InnoCan Pharma Corporation (CSE:INNO)
Canada · Delayed Price · Currency is CAD | Market Cap | 10.57M -80.9% |
| Revenue (ttm) | 33.41M -18.4% |
| Net Income | -1.36M |
| EPS | -0.30 |
| Shares Out | 4.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 154 |
| Open | 2.200 |
| Previous Close | 2.350 |
| Day's Range | 2.200 - 2.200 |
| 52-Week Range | 2.000 - 21.000 |
| Beta | -0.26 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 1, 2026 |
About InnoCan Pharma
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vag... [Read more]
Financial Performance
In 2025, InnoCan Pharma's revenue was $26.61 million, a decrease of -9.60% compared to the previous year's $29.44 million. Losses were -$1.12 million, -38.71% less than in 2024.
Financial numbers in USD Financial StatementsNews
InnoCan Pharma Registration statement: Q2 2026
InnoCan Pharma filed a registration statement on August 31, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q2 2026
InnoCan Pharma released its Q2 2026 earnings on August 31, 2026, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q2 2026
InnoCan Pharma filed a registration statement on August 31, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q1 2026
InnoCan Pharma filed a registration statement on May 27, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q1 2026
InnoCan Pharma filed a registration statement on May 27, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q1 2026
InnoCan Pharma released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
InnoCan Pharma Earnings release: Q4 2025
InnoCan Pharma released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q4 2025
InnoCan Pharma filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q4 2025
InnoCan Pharma filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
HERZLIYA, Israel and CALGARY, AB, March 31, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusi...
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biot...
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biote...
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
HERZLIYA, Israel and CALGARY, AB, Jan. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focus...
InnoCan Pharma Registration statement: Q3 2025
InnoCan Pharma filed a registration statement on November 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q3 2025
InnoCan Pharma filed a registration statement on November 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q3 2025
InnoCan Pharma released its Q3 2025 earnings on November 27, 2025, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q2 2025
InnoCan Pharma filed a registration statement on August 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q2 2025
InnoCan Pharma filed a registration statement on August 27, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q2 2025
InnoCan Pharma released its Q2 2025 earnings on August 27, 2025, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q1 2025
InnoCan Pharma filed a registration statement on May 28, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q1 2025
InnoCan Pharma filed a registration statement on May 28, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Earnings release: Q1 2025
InnoCan Pharma released its Q1 2025 earnings on May 28, 2025, summarizing the period's financial results.
InnoCan Pharma Earnings release: Q4 2024
InnoCan Pharma released its Q4 2024 earnings on March 31, 2025, summarizing the period's financial results.
InnoCan Pharma Registration statement: Q4 2024
InnoCan Pharma filed a registration statement on March 31, 2025, providing details about a securities offering with the SEC.
InnoCan Pharma Registration statement: Q4 2024
InnoCan Pharma filed a registration statement on March 31, 2025, providing details about a securities offering with the SEC.